Experiences with
Trastuzumab emtansine64 public posts
Want to take advantage of all our features? Just log in!
or
First FDA Approved Targeted Therapy for HER2, Enhertu, for the Treatment of NSCLC With an Activating HER2 Mutation
On August 11th, 2022, the Food and Drug Administration (FDA) approved Enhertu (fam- trastuzumab deruxtecan-nxki) for treatment of advanced non-small cell lung cancer (NSCLC) with an activating HER2 mutation for patients who have received one prior line of therapy. The FDA based their approval on the